ライフサイエンスコーパス: saline solution

1 oli in buffered solution (phosphate buffered saline solution).

2 leomycin (control mice were instilled with a saline solution).

3 e remainder of the session) or placebo (0.9% saline solution).

4 form brain tissue when cultured in a simple saline solution.

5 observed until 90 mins after infusion of CO-saline solution.

6 ntrol mice underwent treatment with balanced saline solution.

7 rees C in re-dissolved lyophilized form with saline solution.

8 rom venous catheters were reused to withdraw saline solution.

9 Then the specimens were rinsed in saline solution.

10 d puncture followed by the administration of saline solution.

11 close arterial injection of CO(2)-saturated saline solution.

12 ion followed by the administration of normal saline solution.

13 ion followed by the administration of normal saline solution.

14 t differ in HRs and LRs self-administering a saline solution.

15 atients, 98 (88%) were infused with DCLHb or saline solution.

16 s were to be infused with 500 mL of DCLHb or saline solution.

17 seen with the infusion of phylloquinone in a saline solution.

18 ATAGGCAAAAATGG) at various concentrations of saline solution.

19 by the substitution of Ba2+ for Ca2+ in the saline solution.

20 a regimen previously proved effective, or to saline solution.

21 dogs were reassigned to a course of bFGF or saline solution.

22 n the groups treated initially with bFGF and saline solution.

23 site in charge, and are bactericidal in zinc saline solution.

24 njection of 200 microliters of CO2-saturated saline solution.

25 ompared with a 2400-mosm/L (7.5%) hypertonic saline solution.

26 t value of 44 s-1 were measured at pH 7.5 in saline solution.

27 ushed and stored in HTK-N, TiProtec, HTK, or saline solution.

28 200 mL of either convalescent plasma or 0.9% saline solution.

29 oltages were systematically characterized in saline solution.

30 ter receiving oxytocin compared to receiving saline solution.

31 us SOR-EMs (DLE + SOR-EM); and group 4, with saline solution.

32 , followed by administration of Herceptin or saline solution.

33 n, and 2000 mug/mL of vancomycin in a 200-mL saline solution.

34 in all cell types in roots from the stagnant saline solution.

35 d dilution with less than or equal to 100 mL saline solution.

36 dual HCO3(-) in a nominally CO2/HCO3(-)-free saline solution.

37 , made by bubbling cigarette smoke through a saline solution.

38 intranasal ketamine hydrochloride (50 mg) or saline solution.

39 30 min incubation in Ca2+-free physiological saline solution.

40 trol group, which were given an injection of saline solution.

41 = 6): OVX plus ZOL; SHAM (n = 4): SHAM plus saline solution.

42 and may lead to less hyperkalemia than 0.9% saline solutions.

43 ous tests up to 170 h toward a wide range of saline solutions.

44 PR chips, allowing for bioaffinity assays in saline solutions.

45 of vein grafts in saline, blood, or buffered saline solutions.

46 pper and quinone species in circumneutral pH saline solutions.

47 to that of Ag/AgCl in physiological (0.14 M) saline solutions.

48 ward if rats are denied access to hypertonic saline solutions.

49 CHX (0.12%) and saline solution (0.89% NaCl) were used as positive and n

50 ing HU, rats increased their intakes of both saline solutions (0.9% NaCl (n= 11): control 7.8 +/- 3 m

51 the following treatment groups: 1) SRP plus saline solution; 2) SRP plus low-level laser therapy (LL

52 maximus muscle superfused with physiological saline solution (35 degrees C, pH 7.4; n >/= 5 per group

53 as exposed and superfused with physiological saline solution (35 degrees C; pH 7.4).

54 dal margin of the membrane preparation and a saline solution adjacent to the retinal pigment epitheli

55 vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.

56 ery 10 mins or L-NAME 10 mg/kg in 1 mL/kg of saline solution administered after each hemorrhage for a

57 sensor is alternately exposed to glucose and saline solutions; after each cycle, difference spectra r

58 Use of buffered saline solution also tended to be associated with a lowe

59 mer surface in an aqueous phosphate-buffered saline solution and allowing the peptide solution to dry

60 : negative control group (NCG), treated with saline solution and blood-clot in the alveolus; positive

61 stable colloids, is stable in physiological saline solution and cell culture media, and is not cytot

62 ilicon-nitride chip window from the buffered saline solution and desorb in a temperature-dependent ma

63 o 144 cells/mm2 in the animals that received saline solution and glucose solution, respectively (p =

64 rent concentrations of contrast material and saline solution and injected through various microcathet

65 ction limits at or below 1 ng/mL in buffered saline solution and spiked cell culture medium (CCM) has

66 cted with either gadodiamide, gadobutrol, or saline solution and were killed 1, 3, or 12 months after

67 ts for the monitoring of cytokines in spiked saline solutions and CCM were similar for TNF-alpha and

68 upled receptor (including benign aqueous and saline solutions and in the presence of dodecylphosphoch

69 -41 ((68)Ga-NOTA-UBI29-41) was formulated in saline solution, and 101 +/- 41 MBq were administered in

70 ver, the gluten became soluble in an aqueous saline solution, and it was not possible to isolate it u

71 was then placed into both eyes, rinsed with saline solution, and scanned at 5, 10, 15, and 30 min.

72 peated use, thermal fatigue, irrigation with saline solution, and sterilization process.

73 vailability of i.v. cocaine vs. nonrewarding saline solution, and then placed on extinction condition

74 (SRP) and local irrigation with physiologic saline solution; and 3) SRP/SA group (n = 30), SRP and l

75 at 15 and 30 mins when compared with normal saline solution animals (PaO2 -4% vs. -44%, peak airway

76 in bronchoalveolar lavage fluid from normal saline solution animals at any time.

77 When suspensions of the loaded materials in saline solution are exposed to low-power (10-100 mW) vis

78 shock and multiple-system trauma, hypertonic saline solutions are increasingly being used perioperati

79 es with a prototype microchip using gold and saline solution as a model electrode material and releas

80 gel-filtration column and phosphate buffered saline solution as the mobile phase.

81 ell-stirred and quiescent phosphate-buffered saline solutions as well as in a 0.3% agar solution.

82 during superfusion with bicarbonate-buffered saline solution at 34-36 C.

83 Potentiodynamic measurements, carried out in saline solution at body temperature, showed that the Ti-

84 Biofilms were treated with ozonized saline solution at different concentrations (25, 50, and

85 Biofilms were treated with ozonized saline solution at different concentrations (25, 50, and

86 ain of the MSCRAMMs, in a phosphate-buffered saline solution at neutral pH, were characteristic of a

87 when they are stored in a phosphate-buffered saline solution at pH 7.4.

88 With a saline solution at physiological pH, an Arixtra molecule

89 e (LPS; 100 ug/kg, i.p.) or vehicle control (saline solution) at postnatal day 14 (P14).

90 omized to receive either glucose solution or saline solution before the induced injury and the sham i

91 e dissipated energy (CDE) and total balanced saline solution (BSS) data were obtained at the end of e

92 Mitomycin-C (MMC) and balanced saline solution (BSS) treatment acted as positive and ne

93 Physiologic saline solution (BSS; Alcon, Ft. Worth, TX) was injected

94 across the cortex in roots from the aerated saline solution but was relatively high in all cell type

95 eptides are immunogenic when administered in saline solution by either subcutaneous or intranasal rou

96 ry electrolytes and responses to infusion of saline solutions can distinguish between syndrome of app

97 rent doses of carbon monoxide (CO)-saturated saline solutions (CO-saline) affect microvascular and sy

98 ed with a negative unconditioned stimulus of saline solution, cockroaches conditioned in the early su

99 PTA per minute in a pH 7.40 phosphate buffer saline solution containing 10% dimethyl sulfoxide (DMSO)

100 esthesia, live bacteria suspended in a 30-mL saline solution containing 2-5 x 10(11) colony-forming u

101 ng catheter, the infusion of a physiological saline solution containing 4% BSA resulted in a marked n

102 RNS60 is a 0.9% saline solution containing charge-stabilized nanostructu

103 A tube with flowing saline solution containing contrast agent was positioned

104 A single subretinal injection of saline solution containing fluorescent beads caused a hi

105 HEPES-buffered physiological saline solution containing pEGFP plasmid at a low concen

106 ructure and salt retention of ice grown from saline solutions containing EPS from a culture of the se

107 /wt ethanol solution (ethanol group) or 0.9% saline solution (control group) at the end of DC inserti

108 oups of six rats with HCC were injected with saline solution (control group); CA4P, Dox-loaded PEG-co

109 animals were randomized to receive nebulized saline solution (CONTROL); nebulized amikacin every 6 ho

110 ity of phenanthrene (chemical stress), while saline solutions controlled the water activity (drought

111 ham laparotomy and intrasplenic injection of saline solution; CsA given alone to dalmatians did not m

112 emical extraction were performed with enzyme saline solutions, deionized water, and 50% (v/v) aqueous

113 andling and intraperitoneal injection with a saline solution), demonstrating the sensitivity of the t

114 d to each of the following treatment groups: saline solution, dexamethasone sodium phosphate, a nonpa

115 se of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mort

116 8 (17%) of the 46 patients infused with the saline solution died (P = .003).

117 7 (15%) of the 46 patients infused with the saline solution died (P = .01).

118 of contrast material pushed with injectable saline solution during thoracic computed tomography (CT)

119 In general, concentrated saline solutions elicit robust behavioural aversion, whe

120 ced unilaterally, by injection of hypertonic saline solution, episcleral vein cauterization, or optic

121 diacerein while in PSG, the animals received saline solution for 7, 15, and 30 days.

122 tion of administration and to high volume of saline solution for dilution.

123 RNS60 is a 0.9% saline solution generated by subjecting normal saline to

124 kg daily on 2 consecutive days), or placebo (saline solution given in the same manner as IVIG).

125 nder high pressure, high temperature, and in saline solutions, greatly enhancing the efficiency and f

126 rway pressure 28% vs. 69% at 30 mins; normal saline solution group vs. human gastric juice group, p <

127 2 +/- 0.5 vs. 6.4 +/- 0.4 at 60 mins, normal saline solution group vs. human gastric juice group, p =

128 and five of eight animals at 60 mins (normal saline solution group vs. human gastric juice group; p <

129 ns (human gastric juice group, n = 8; normal saline solution group, n = 4) postaspiration.

130 ns (human gastric juice group, n = 8; normal saline solution group, n = 4), 30 mins (human gastric ju

131 ns (human gastric juice group, n = 8; normal saline solution group, n = 4), or 60 mins (human gastric

132 rmal saline solution (pH 5.2 +/- 0.2; normal saline solution group; n = 12).

133 isulfite-free IPH 1.5% (group 1) or balanced saline solution (group 2) at the start of surgery.

134 C) storage in either buffered physiological saline solution (group 2) or UW solution (group 3).

135 comparison with control arteries exposed to saline solution (group 2).

136 ose vein grafts were preserved in a buffered saline solution had lower VGF rates and trends toward be

137 with laryngomalacia, application of a normal saline solution had no effect on the laryngomalacia scor

138 addition of steroids and anesthetics to the saline solutions had no impact on the signal intensity c

139 Ozonized saline solution has antibiofilm activity, with better ef

140 Ozonized saline solution has antibiofilm activity, with better ef

141 luctuating concentration of ascorbic acid in saline solution has been confirmed.

142 h medium for 3 days and with Hanks' buffered saline solution (HBSS) for 4 hours.

143 own to confluence, washed in Hank's balanced saline solution (HBSS), and then cultured for 72 hours i

144 n and with the changes induced by hypertonic saline solution (HSS) treatment.

145 ave ascorbic acid administered alone or with saline solution hydration.

146 ion followed by the administration of normal saline solution (i.e., fluid resuscitation).

147 ion followed by the administration of normal saline solution (i.e., fluid resuscitation).

148 ion followed by the administration of normal saline solution (i.e., fluid resuscitation).

149 ion followed by the administration of normal saline solution (i.e., fluid resuscitation).

150 ects during the "placebo" infusion (isotonic saline solution) immediately preceding the lactate infus

151 1-2 h infusion, day -6; thiotepa 5 mg/kg in saline solution in a 2 h infusion every 12 h, days -5 an

152 ogs, resuscitation was performed with normal saline solution in a volume equal to the total volume of

153 allenge with antigen in one segment and with saline solution in another.

154 timicrobial effect of ozonized physiological saline solution in different concentrations against oral

155 th 90 mM Ba2+ in the pipette and physiologic saline solution in the bath.

156 digo carmine (0.05 mg/mL diluted in balanced saline solution) in the presence of high-brightness xeno

157 detection of urea between 78muM and 20mM in saline solution, in sample volumes of just 50muL.

158 anx1) were exposed to alkaline extracellular saline solution, increasing the activity of Panx1 HCs.

159 eptides in 0.14 M NaCl/10 microM ZnCl2 (zinc saline solution) induced killing of P. haemolytica and o

160 e intracameral antibiotics (via the balanced saline solution infusion), and postoperative impregnated

161 , and injection of intact cells suspended in saline solution), injection of lysed blood provided the

162 erformed with injection of 10 ml of agitated saline solution into branch pulmonary arteries.

163 Control mice received saline solution intratracheally (0.05 mL, pulmonary cont

164 Control mice (Healthy) received saline solution intratracheally (Cp) or intraperitoneall

165 eparin/protamine titrations in physiological saline solutions is demonstrated.

166 The dye, dissolved in normal saline solution, is added to a chamber containing the pr

167 in response to 51 mM potassium physiological saline solution (KCl).

168 3 mm HCO3(-) to an O2-gassed, HEPES-buffered saline solution lowered the intracellular H(+) concentra

169 omized trials have suggested that hypertonic saline solutions may be superior to mannitol for the tre

170 between the LODs of the GeneXpert assay with saline solution (median, 33 CFU/ml) and CSF (median, 25

171 her 1.25 g/kg ioxilan (n = 10) or hypertonic saline solution (n = 10) as a control.

172 00-mL saline solution (n = 113) or a placebo saline solution (n = 110) at baseline and 12 months.

173 h either 5 mg of zoledronic acid in a 100-mL saline solution (n = 113) or a placebo saline solution (

174 prophylaxis with ciprofloxacin (n = 112) or saline solution (n = 114, placebo).

175 nd atherosclerotic mice were injected with a saline solution (n = 2).

176 8 mug/2 muL of 6-hydroxydopamine (n = 6) or saline solution (n = 4) in the right medial forebrain bu

177 ither a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids.

178 olysates by means of alkaline-hydroalcoholic saline solutions (NaOH: 0.54 M, EtOH: 1.17 v, NaCl: 2.5%

179 TM) or sodium alginate (reference sample) or saline solution (negative control) or acid solution (pos

180 method was validated with the blinded use of saline solutions of varying sodium concentrations.

181 ochloride (0.4 mg/kg), m-CPP (1.0 mg/kg), or saline solution on 3 separate test days in a randomized

182 ors undergoing cardiac surgery and stored in saline solution on ice until transplantation.

183 Mice that received phosphate-buffered saline solution only were included as nonadoptive-transf

184 12) were treated subcutaneously with either saline solution or 0.3 mg/kg body weight of meloxicam da

185 pproximately 18 mice, were fed either normal saline solution or 15 mg/kg fluvastatin for 15 days.

186 ere intravenously administered with either a saline solution or a recombinant human erythropoietin (5

187 ll inflated either by external injections of saline solution or air, or by internal osmotic pressure

188 nterval, type of contrast agent (eg, sterile saline solution or water), and quantity of contrast agen

189 ation can be altered via the electrolysis of saline solutions or deionized water.

190 ly elevated compared to that determined with saline solution (P </= 0.05 and </= 0.0005, respectively

191 yoglobin, and lysozyme as test proteins in a saline solution, passed through the SR, are demonstrated

192 human gastric juice group, n = 24) or normal saline solution (pH 5.2 +/- 0.2; normal saline solution

193 water-soluble chlorins in phosphate-buffered saline solution (pH 7.4) at room temperature were invest

194 hort echo times (0.4 msec) by using external saline solution phantoms for reference.

195 oculated with a selected BMC consortium or a saline solution placebo.

196 njection of 120 million Cx601 cells or 24 mL saline solution (placebo), with stratification according

197 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo).

198 eceive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard

199 ed when 40 mM KCl was added to physiological saline solution (PSS) (peak value assigned 100%), and th

200 Preincubating IPAs in physiological saline solution (PSS) containing 1 mm cysteine increased

201 nisolone, 0.025% doxycycline, or physiologic saline solution (PSS) four times per day.

202 gions, nine healthy women tasted an aversive saline solution, pure water and chocolate while rCBF was

203 paration (fresh serum) and immediately after saline solution reconstitution of lyophilized serum (0),

204 sec) (23)Na images to those from an external saline solution reference.

205 ed mapping and the use of highly evaporative saline solutions regardless of ambient humidity levels.

206 ifferent fluid types (a balanced solution vs saline solution reported in this article) and 2 differen

207 t of cimetidine (cimetidine group [CimG]) or saline solution (sham group [SG]).

208 90% phenol (denervation group [PDN]) or 0.9% saline solution (sham-operated group [SHAM]).

209 Ozonized saline solution showed antibiofilm activity at a concent

210 Ozonized saline solution showed antibiofilm activity at a concent

211 line, addition of blood or plasma to the air-saline solution significantly increased the concentratio

212 After systemic administration of hypertonic saline solutions, significantly more water was consumed

213 0 min) incubation in Ca2+-free physiological saline solution similarly reduced phase 2 but abolished

214 After volume replacement with normal saline solution, SMV %HbO2 and flow were not significant

215 ipratropium bromide (84 microgram) or normal saline solution sprayed into the nasal cavity 15 min bef

216 uring stable bromine isotope compositions in saline solutions such as seawater, brines, and formation

217 e of extracellular Ca2+ and also in Na+-free saline solutions, suggesting that hyperpolarisation lead

218 3-phosphocholine lipid bilayers in different saline solutions, that ions can locally induce ordering

219 roup 1 (control): subcutaneous injections of saline solution, three times a week (n = 15); group 2: 2

220 ance, PBS = phosphate-buffered physiological saline solution, TMJ = temporomandibular joint, mu(T) =t

221 -STb-bound T84 and HT29 cells with an acidic saline solution to remove surface-bound toxin revealed t

222 two subconjunctival injections of DMSO or of saline solution to right eyes only or they remained untr

223 el), rats were IV administered with either a saline solution (traumatic brain injury-saline group) or

224 vival rate of Prototheca in milk compared to saline solution treated under the same conditions.

225 ither intravenous MP (0.5 mg/kg) or placebo (saline solution) twice daily for 5 days.

226 ne hydrochloride (0.1 mg/kg or 0.5 mg/kg) or saline solution under randomized double-blind conditions

227 eformation and exposure to lossy, conductive saline solutions, underscoring its potential application

228 The 20% hypertonic saline solution was administered for 48 hours or longer

229 le injection of depot medroxyprogesterone or saline solution was administered.

230 A similar volume of normal saline solution was injected subconjunctivally in the le

231 Balanced saline solution was injection into the left eye of each

232 recovery, 10 mL/kg of 20% meconium in normal saline solution was insufflated into the lungs.

233 emolytica incubated with H-DDDDDD-OH in zinc saline solution was killed within 30 min.

234 After 24 hours, the protein content of the saline solution was measured by standard assay and perme

235 Saline solution was used as a negative control.

236 re, glycine (0.6 mmol/kg) or vehicle (normal saline solution) was administered intravenously over 15

237 Sialidase (or saline solution) was infused to the injury site continuo

238 n dose injected into young outbred mice as a saline solution, were bactericidal against B. pertussis,

239 etection limit of 0.005 unit/mL heparin in a saline solution, which is slightly lower than the detect

240 ed by supplementing the bicarbonate-buffered saline solution with HEPES.

241 the 1a film was found in phosphate-buffered saline solution with TPrA.

242 phosphate and dopamine in phosphate-buffered saline solution, with and without 10% fetal bovine serum

243 % of cells, whereas the exposure to alkaline saline solution without Ca(2+) failed to induce cell dea

244 ministration twice (at a 2-wk interval) with saline solution, WT Spn6B (BHN418), or one of two geneti

245 1 is designed to be unstructured in buffered saline solution, yet undergo HA-induced folding that is

246 re treated as follows: OVX (n = 5): OVX plus saline solution; zoledronic acid-treated group (ZOL) (n